What are the recommended routes of insulin administration for patients with diabetes?

Insulin Routes of Administration

Insulin must be administered subcutaneously into the abdomen, thigh, buttock, or upper arm—never intramuscularly—as the standard route for all patients with diabetes requiring insulin therapy. 1

Primary Route: Subcutaneous Injection

The subcutaneous route is the established standard for insulin delivery, with specific anatomical sites recommended based on absorption characteristics and safety profiles. 1, 2

Approved Injection Sites

• Abdomen: Provides the fastest and most consistent insulin absorption 3
• Thigh: Acceptable alternative site with slightly slower absorption 1
• Buttock: Recommended truncal site that reduces risk of intramuscular injection 1, 4
• Upper arm: Appropriate site but requires careful technique 1, 2

Critical Technical Requirements

Avoid intramuscular injection at all costs—IM delivery causes unpredictable insulin absorption, variable glycemic effects, and is strongly associated with frequent unexplained hypoglycemia. 1, 5 The risk of inadvertent IM injection increases in:

• Younger, leaner individuals 1, 4
• Injections into limbs (arms/legs) rather than truncal sites (abdomen/buttocks) 1, 4
• Use of needles longer than 4-6 mm 1, 4

Use 4-mm pen needles as first-line for all patient categories—these short needles are safe, effective, less painful, and significantly reduce the risk of intramuscular injection, even in patients with obesity. 1, 4, 6

Alternative Routes Available

Continuous Subcutaneous Insulin Infusion (CSII)

Insulin pumps deliver rapid-acting insulin analogs continuously via subcutaneous infusion, with the same anatomical site requirements as injections. 1 This includes:

• Standard insulin pumps 1, 7
• Automated insulin delivery (AID) systems with hybrid closed-loop technology 1
• Insulin patch pumps 1

Inhaled Insulin (Oral Inhalation)

Inhaled human insulin is FDA-approved for prandial (mealtime) insulin delivery and may be used in place of injectable rapid-acting insulin in the United States. 1, 2 This route:

• Provides an alternative for patients with needle aversion 7
• Requires proper inhaler technique and reservoir filling 1
• Is not suitable for basal insulin replacement 2

Site Rotation Protocol

Implement systematic rotation within one anatomical area to prevent lipohypertrophy—soft, raised areas of accumulated subcutaneous fat that cause erratic insulin absorption, increased glycemic variability, and unexplained hypoglycemia. 1, 2, 5

• Rotate injection sites at each administration 1, 8
• Never inject into areas of lipohypertrophy 2, 5
• Examine injection sites regularly for lipohypertrophy development 2, 5
• Educate patients to recognize and avoid affected areas 1, 2

Delivery Device Options

Selection depends on patient-specific factors, cost, coverage, and preferences, but all deliver insulin subcutaneously: 1

• Vials and syringes: Traditional method, most economical 1, 7
• Insulin pens: Improved convenience and accuracy, especially for patients with dexterity issues or vision impairment 7
• Connected insulin pens/smart pens: Provide dose capture and dosing recommendations 7
• Insulin pumps: Continuous delivery with programmable basal rates 1
• Insulin patches: Bolus delivery via subcutaneous infusion 1

Routes NOT Recommended

Intravenous insulin is reserved exclusively for hospital settings in critically ill patients and is not appropriate for outpatient diabetes management. 3

Experimental routes under investigation (oral, buccal, nasal, peritoneal, transdermal) are not currently approved for clinical use and should not be considered for routine diabetes care. 9, 10

Common Pitfalls to Avoid

• Using needles longer than 6 mm: Increases intramuscular injection risk, particularly in children and lean adults 4, 6
• Injecting into limbs in lean patients: Significantly increases IM injection risk—prefer truncal sites (abdomen, buttocks) 1, 4
• Failing to rotate sites: Leads to lipohypertrophy with unpredictable insulin absorption 1, 2, 5
• Mixing or diluting insulin glargine: This long-acting insulin must never be diluted or mixed with other insulins 8
• Reusing needles: While common due to cost constraints, needle reuse is associated with lipohypertrophy development and is not manufacturer-recommended 6

Administration Technique Reassessment

Verify proper injection technique at every routine follow-up visit—this includes checking injection sites for lipohypertrophy, confirming appropriate needle length, and ensuring correct site rotation practices. 1, 2